Relevance of leukaemia inhibitory factor to anti-melanoma differentiation-associated gene 5 antibody-positive interstitial lung disease

Abstract Objectives Anti-melanoma differentiation-associated gene 5 (MDA5) antibody-positive rapidly progressive interstitial lung disease (RP-ILD) is a life-threatening disease, the aetiology of which remains unclear. To detect potential diagnostic markers, a transcriptome analysis of the lung samp...

Full description

Saved in:
Bibliographic Details
Published inRheumatology (Oxford, England) Vol. 62; no. 6; pp. 2267 - 2271
Main Authors Ichimura, Yuki, Ikei, Hiroyuki, Konishi, Risa, Zeniya, Moko, Okai, Takahiro, Nomura, Toshifumi, Negishi, Kousuke, Okiyama, Naoko
Format Journal Article
LanguageEnglish
Published England Oxford University Press 01.06.2023
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Abstract Objectives Anti-melanoma differentiation-associated gene 5 (MDA5) antibody-positive rapidly progressive interstitial lung disease (RP-ILD) is a life-threatening disease, the aetiology of which remains unclear. To detect potential diagnostic markers, a transcriptome analysis of the lung sample from a patient with anti-MDA5 antibody-positive RP-ILD was performed. Methods RNA sequencing analyses of an autopsy lung sample from a 74-year-old woman with anti-MDA5 antibody-positive RP-ILD was performed and compared with an age- and sex-matched normal lung sample. Genes with changes of gene expression ≥5-fold were considered differentially expressed genes and analysed by Metascape. The levels of leukaemia inhibitory factor (LIF) were measured in the serum samples from 12 cases of anti-MDA5 antibody-positive ILD, 12 cases of anti-aminoacyl tRNA synthetase (ARS) antibody-positive ILD, 10 cases of anti-transcription intermediary factor 1γ/anti-Mi-2 antibody DM and 12 healthy volunteers. Results Gene ontology enrichment analysis on the RNA sequencing data showed a strong association with antigen binding. Upregulated expressions of IL-1β, IL-6 and LIF were also detected. Serum LIF levels were significantly elevated in anti-MDA5 antibody-positive ILD patients {median 32.4 pg/ml [interquartile range (IQR) 13.2–125.7]} when compared with anti-ARS antibody-positive ILD patients [4.9 pg/ml (IQR 3.1–19.7), P < 0.05] and DM patients [5.3 pg/ml (IQR 3.9–9.7), P < 0.05]. Conclusion Our present study suggested that upregulation of LIF might be a new potential disease marker specific for anti-MDA5 antibody-positive ILD.
AbstractList Anti-melanoma differentiation-associated gene 5 (MDA5) antibody-positive rapidly progressive interstitial lung disease (RP-ILD) is a life-threatening disease, the aetiology of which remains unclear. To detect potential diagnostic markers, a transcriptome analysis of the lung sample from a patient with anti-MDA5 antibody-positive RP-ILD was performed. RNA sequencing analyses of an autopsy lung sample from a 74-year-old woman with anti-MDA5 antibody-positive RP-ILD was performed and compared with an age- and sex-matched normal lung sample. Genes with changes of gene expression ≥5-fold were considered differentially expressed genes and analysed by Metascape. The levels of leukaemia inhibitory factor (LIF) were measured in the serum samples from 12 cases of anti-MDA5 antibody-positive ILD, 12 cases of anti-aminoacyl tRNA synthetase (ARS) antibody-positive ILD, 10 cases of anti-transcription intermediary factor 1γ/anti-Mi-2 antibody DM and 12 healthy volunteers. Gene ontology enrichment analysis on the RNA sequencing data showed a strong association with antigen binding. Upregulated expressions of IL-1β, IL-6 and LIF were also detected. Serum LIF levels were significantly elevated in anti-MDA5 antibody-positive ILD patients {median 32.4 pg/ml [interquartile range (IQR) 13.2-125.7]} when compared with anti-ARS antibody-positive ILD patients [4.9 pg/ml (IQR 3.1-19.7), P < 0.05] and DM patients [5.3 pg/ml (IQR 3.9-9.7), P < 0.05]. Our present study suggested that upregulation of LIF might be a new potential disease marker specific for anti-MDA5 antibody-positive ILD.
Anti-melanoma differentiation-associated gene 5 (MDA5) antibody-positive rapidly progressive interstitial lung disease (RP-ILD) is a life-threatening disease, the aetiology of which remains unclear. To detect potential diagnostic markers, a transcriptome analysis of the lung sample from a patient with anti-MDA5 antibody-positive RP-ILD was performed.OBJECTIVESAnti-melanoma differentiation-associated gene 5 (MDA5) antibody-positive rapidly progressive interstitial lung disease (RP-ILD) is a life-threatening disease, the aetiology of which remains unclear. To detect potential diagnostic markers, a transcriptome analysis of the lung sample from a patient with anti-MDA5 antibody-positive RP-ILD was performed.RNA sequencing analyses of an autopsy lung sample from a 74-year-old woman with anti-MDA5 antibody-positive RP-ILD was performed and compared with an age- and sex-matched normal lung sample. Genes with changes of gene expression ≥5-fold were considered differentially expressed genes and analysed by Metascape. The levels of leukaemia inhibitory factor (LIF) were measured in the serum samples from 12 cases of anti-MDA5 antibody-positive ILD, 12 cases of anti-aminoacyl tRNA synthetase (ARS) antibody-positive ILD, 10 cases of anti-transcription intermediary factor 1γ/anti-Mi-2 antibody DM and 12 healthy volunteers.METHODSRNA sequencing analyses of an autopsy lung sample from a 74-year-old woman with anti-MDA5 antibody-positive RP-ILD was performed and compared with an age- and sex-matched normal lung sample. Genes with changes of gene expression ≥5-fold were considered differentially expressed genes and analysed by Metascape. The levels of leukaemia inhibitory factor (LIF) were measured in the serum samples from 12 cases of anti-MDA5 antibody-positive ILD, 12 cases of anti-aminoacyl tRNA synthetase (ARS) antibody-positive ILD, 10 cases of anti-transcription intermediary factor 1γ/anti-Mi-2 antibody DM and 12 healthy volunteers.Gene ontology enrichment analysis on the RNA sequencing data showed a strong association with antigen binding. Upregulated expressions of IL-1β, IL-6 and LIF were also detected. Serum LIF levels were significantly elevated in anti-MDA5 antibody-positive ILD patients {median 32.4 pg/ml [interquartile range (IQR) 13.2-125.7]} when compared with anti-ARS antibody-positive ILD patients [4.9 pg/ml (IQR 3.1-19.7), P < 0.05] and DM patients [5.3 pg/ml (IQR 3.9-9.7), P < 0.05].RESULTSGene ontology enrichment analysis on the RNA sequencing data showed a strong association with antigen binding. Upregulated expressions of IL-1β, IL-6 and LIF were also detected. Serum LIF levels were significantly elevated in anti-MDA5 antibody-positive ILD patients {median 32.4 pg/ml [interquartile range (IQR) 13.2-125.7]} when compared with anti-ARS antibody-positive ILD patients [4.9 pg/ml (IQR 3.1-19.7), P < 0.05] and DM patients [5.3 pg/ml (IQR 3.9-9.7), P < 0.05].Our present study suggested that upregulation of LIF might be a new potential disease marker specific for anti-MDA5 antibody-positive ILD.CONCLUSIONOur present study suggested that upregulation of LIF might be a new potential disease marker specific for anti-MDA5 antibody-positive ILD.
Abstract Objectives Anti-melanoma differentiation-associated gene 5 (MDA5) antibody-positive rapidly progressive interstitial lung disease (RP-ILD) is a life-threatening disease, the aetiology of which remains unclear. To detect potential diagnostic markers, a transcriptome analysis of the lung sample from a patient with anti-MDA5 antibody-positive RP-ILD was performed. Methods RNA sequencing analyses of an autopsy lung sample from a 74-year-old woman with anti-MDA5 antibody-positive RP-ILD was performed and compared with an age- and sex-matched normal lung sample. Genes with changes of gene expression ≥5-fold were considered differentially expressed genes and analysed by Metascape. The levels of leukaemia inhibitory factor (LIF) were measured in the serum samples from 12 cases of anti-MDA5 antibody-positive ILD, 12 cases of anti-aminoacyl tRNA synthetase (ARS) antibody-positive ILD, 10 cases of anti-transcription intermediary factor 1γ/anti-Mi-2 antibody DM and 12 healthy volunteers. Results Gene ontology enrichment analysis on the RNA sequencing data showed a strong association with antigen binding. Upregulated expressions of IL-1β, IL-6 and LIF were also detected. Serum LIF levels were significantly elevated in anti-MDA5 antibody-positive ILD patients {median 32.4 pg/ml [interquartile range (IQR) 13.2–125.7]} when compared with anti-ARS antibody-positive ILD patients [4.9 pg/ml (IQR 3.1–19.7), P < 0.05] and DM patients [5.3 pg/ml (IQR 3.9–9.7), P < 0.05]. Conclusion Our present study suggested that upregulation of LIF might be a new potential disease marker specific for anti-MDA5 antibody-positive ILD.
Author Negishi, Kousuke
Ikei, Hiroyuki
Ichimura, Yuki
Okai, Takahiro
Nomura, Toshifumi
Okiyama, Naoko
Konishi, Risa
Zeniya, Moko
Author_xml – sequence: 1
  givenname: Yuki
  surname: Ichimura
  fullname: Ichimura, Yuki
– sequence: 2
  givenname: Hiroyuki
  surname: Ikei
  fullname: Ikei, Hiroyuki
– sequence: 3
  givenname: Risa
  orcidid: 0000-0003-3681-2441
  surname: Konishi
  fullname: Konishi, Risa
– sequence: 4
  givenname: Moko
  surname: Zeniya
  fullname: Zeniya, Moko
– sequence: 5
  givenname: Takahiro
  surname: Okai
  fullname: Okai, Takahiro
– sequence: 6
  givenname: Toshifumi
  surname: Nomura
  fullname: Nomura, Toshifumi
– sequence: 7
  givenname: Kousuke
  surname: Negishi
  fullname: Negishi, Kousuke
– sequence: 8
  givenname: Naoko
  orcidid: 0000-0002-5398-0773
  surname: Okiyama
  fullname: Okiyama, Naoko
  email: okiy.derm@tmd.ac.jp
BackLink https://www.ncbi.nlm.nih.gov/pubmed/36326445$$D View this record in MEDLINE/PubMed
BookMark eNqNkV1rFDEUhoNU7Jf_QCSX3ow7-ZjJrHdSbCsUBLHX4SRzso3NTNYkU9hf4N9u7G5FvNGr88HzvnDOe0qO5jgjIW9Y-561a7FKd7hMUGKIm93qHsH2gr8gJ0z2vGmF4Ee_ey6PyWnO39u27ZgYXpFjUdleyu6E_PyKAR9gtkijowGXe8DJA_XznTe-xLSjDmyttEQKc_HNhAHmOAEdvXOYsO6g-Dg3kHO0tceRbnBG2j3xJo67ZhuzL_4Bq23BlEsdINCwzJvqkhEynpOXDkLG14d6Rm4vP327uG5uvlx9vvh401ghVWk656QyRjnLpRp51yvTDz3aQVllhDWta8eul9ysmerZgGPnxn5EC3YNA-dWnJF3e99tij8WzEVPPlsM9SaMS9ZcCabYwLuhom8P6GImHPU2-QnSTj8_rwIf9oBNMeeETltfnn5REvigWat_JaX_TEofkqpi-Zf42f8fstVeFpft_ykeAaXYs-U
CitedBy_id crossref_primary_10_1073_pnas_2313070121
Cites_doi 10.1136/annrheumdis-2017-211468
10.1186/s12865-014-0041-4
10.1006/cyto.1996.9999
10.1093/rheumatology/key386
10.1097/BOR.0000000000000329
10.1093/rheumatology/keu258
10.1093/rheumatology/kes102
10.1093/rheumatology/keab371
10.1002/art.21023
10.3390/biom12020217
ContentType Journal Article
Copyright The Author(s) 2022. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com 2022
The Author(s) 2022. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com.
Copyright_xml – notice: The Author(s) 2022. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com 2022
– notice: The Author(s) 2022. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com.
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOI 10.1093/rheumatology/keac632
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE
MEDLINE - Academic

Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1462-0332
EndPage 2271
ExternalDocumentID 36326445
10_1093_rheumatology_keac632
10.1093/rheumatology/keac632
Genre Journal Article
Case Reports
GroupedDBID ---
-E4
.2P
.GJ
.I3
.XZ
.ZR
08P
0R~
18M
1TH
29P
2WC
354
3O-
4.4
48X
53G
5RE
5VS
5WA
5WD
70D
AABZA
AACZT
AAGKA
AAJKP
AAJQQ
AAMDB
AAMVS
AAOGV
AAPGJ
AAPNW
AAPQZ
AAPXW
AARHZ
AAUAY
AAUQX
AAVAP
AAWDT
AAWTL
ABDFA
ABEJV
ABEUO
ABGNP
ABIXL
ABJNI
ABKDP
ABLJU
ABNGD
ABNHQ
ABNKS
ABOCM
ABPTD
ABQLI
ABQNK
ABQTQ
ABVGC
ABXVV
ABZBJ
ACFRR
ACGFO
ACGFS
ACPRK
ACUFI
ACUKT
ACUTJ
ACUTO
ACYHN
ADBBV
ADEYI
ADEZT
ADGZP
ADHKW
ADHZD
ADIPN
ADMTO
ADNBA
ADOCK
ADQBN
ADRTK
ADVEK
ADYVW
ADZXQ
AEGPL
AEGXH
AEHUL
AEJOX
AEKSI
AEMDU
AEMQT
AENEX
AENZO
AEPUE
AETBJ
AEWNT
AFFNX
AFFZL
AFIYH
AFOFC
AFXAL
AGINJ
AGKEF
AGSYK
AGUTN
AHMBA
AHMMS
AHXPO
AIAGR
AIJHB
AJEEA
AJNCP
AKWXX
ALMA_UNASSIGNED_HOLDINGS
ALUQC
ALXQX
APIBT
APWMN
AQDSO
ATGXG
ATTQO
AXUDD
AZFZN
BAWUL
BAYMD
BCRHZ
BEYMZ
BHONS
BTRTY
BVRKM
C45
CAG
CDBKE
COF
CS3
CZ4
DAKXR
DIK
DILTD
DU5
D~K
E3Z
EBD
EBS
EE~
EIHJH
EJD
EMOBN
ENERS
F5P
F9B
FECEO
FEDTE
FLUFQ
FOEOM
FOTVD
FQBLK
GAUVT
GJXCC
GX1
H13
H5~
HAR
HVGLF
HW0
HZ~
IOX
J21
JXSIZ
KAQDR
KBUDW
KOP
KQ8
KSI
KSN
L7B
M-Z
M49
MHKGH
N9A
NGC
NOMLY
NOYVH
NTWIH
NU-
NVLIB
O0~
O9-
OAUYM
OAWHX
OBH
OCZFY
ODMLO
OHH
OJQWA
OJZSN
OPAEJ
OVD
OWPYF
O~Y
P2P
PAFKI
PB-
PEELM
PQQKQ
Q1.
Q5Y
R44
RD5
RIG
RNI
ROL
ROX
RUSNO
RW1
RXO
RZF
RZO
SV3
TCURE
TEORI
TJX
TMA
TR2
VVN
W8F
WOQ
X7H
YAYTL
YKOAZ
YXANX
ZGI
ZKX
ZY1
~91
AAYXX
AGORE
AHGBF
AJBYB
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
ID FETCH-LOGICAL-c347t-5ff47bb7fc247d2567b686ec87c7b3cb0f0d5642b917618ed5fd6decac9a822c3
ISSN 1462-0324
1462-0332
IngestDate Fri Jul 11 09:26:12 EDT 2025
Thu Apr 03 07:07:12 EDT 2025
Thu Apr 24 22:57:38 EDT 2025
Tue Jul 01 04:04:37 EDT 2025
Wed Apr 02 07:05:42 EDT 2025
IsPeerReviewed true
IsScholarly true
Issue 6
Keywords anti-melanoma differentiation-associated gene 5 antibody
leukaemia inhibitory factor
DM
transcriptome analysis
Language English
License This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/pages/standard-publication-reuse-rights)
https://academic.oup.com/pages/standard-publication-reuse-rights
The Author(s) 2022. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com.
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c347t-5ff47bb7fc247d2567b686ec87c7b3cb0f0d5642b917618ed5fd6decac9a822c3
Notes ObjectType-Case Study-2
SourceType-Scholarly Journals-1
ObjectType-Feature-4
content type line 23
ObjectType-Report-1
ObjectType-Article-3
ORCID 0000-0003-3681-2441
0000-0002-5398-0773
PMID 36326445
PQID 2731718258
PQPubID 23479
PageCount 5
ParticipantIDs proquest_miscellaneous_2731718258
pubmed_primary_36326445
crossref_citationtrail_10_1093_rheumatology_keac632
crossref_primary_10_1093_rheumatology_keac632
oup_primary_10_1093_rheumatology_keac632
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2023-06-01
20230601
PublicationDateYYYYMMDD 2023-06-01
PublicationDate_xml – month: 06
  year: 2023
  text: 2023-06-01
  day: 01
PublicationDecade 2020
PublicationPlace England
PublicationPlace_xml – name: England
PublicationTitle Rheumatology (Oxford, England)
PublicationTitleAlternate Rheumatology (Oxford)
PublicationYear 2023
Publisher Oxford University Press
Publisher_xml – name: Oxford University Press
References Lundberg (2023060113241511500_keac632-B1) 2017; 76
Jorgensen (2023060113241511500_keac632-B7) 2022; 12
Gono (2023060113241511500_keac632-B4) 2014; 53
Gono (2023060113241511500_keac632-B5) 2022; 61
Fujimoto (2023060113241511500_keac632-B2) 2016; 28
Foronjy (2023060113241511500_keac632-B9) 2014; 15
Ono (2023060113241511500_keac632-B10) 2019; 58
Jorens (2023060113241511500_keac632-B8) 1996; 8
Sato (2023060113241511500_keac632-B3) 2005; 52
Gono (2023060113241511500_keac632-B6) 2012; 51
References_xml – volume: 76
  start-page: 1955
  year: 2017
  ident: 2023060113241511500_keac632-B1
  article-title: 2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups
  publication-title: Ann Rheum Dis
  doi: 10.1136/annrheumdis-2017-211468
– volume: 15
  start-page: 41
  year: 2014
  ident: 2023060113241511500_keac632-B9
  article-title: Leukemia inhibitory factor protects the lung during respiratory syncytial viral infection
  publication-title: BMC Immunol
  doi: 10.1186/s12865-014-0041-4
– volume: 8
  start-page: 873
  year: 1996
  ident: 2023060113241511500_keac632-B8
  article-title: High levels of leukaemia inhibitory factor in ARDS
  publication-title: Cytokine
  doi: 10.1006/cyto.1996.9999
– volume: 58
  start-page: 786
  year: 2019
  ident: 2023060113241511500_keac632-B10
  article-title: The relationship between type 1 IFN and vasculopathy in anti-MDA5 antibody-positive dermatomyositis patients
  publication-title: Rheumatology (Oxford)
  doi: 10.1093/rheumatology/key386
– volume: 28
  start-page: 636
  year: 2016
  ident: 2023060113241511500_keac632-B2
  article-title: Recent advances in dermatomyositis-specific autoantibodies
  publication-title: Curr Opin Rheumatol
  doi: 10.1097/BOR.0000000000000329
– volume: 53
  start-page: 2196
  year: 2014
  ident: 2023060113241511500_keac632-B4
  article-title: Cytokine profiles in polymyositis and dermatomyositis complicated by rapidly progressive or chronic interstitial lung disease
  publication-title: Rheumatology (Oxford)
  doi: 10.1093/rheumatology/keu258
– volume: 51
  start-page: 1563
  year: 2012
  ident: 2023060113241511500_keac632-B6
  article-title: Anti-MDA5 antibody, ferritin and IL-18 are useful for the evaluation of response to treatment in interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis
  publication-title: Rheumatology (Oxford)
  doi: 10.1093/rheumatology/kes102
– volume: 61
  start-page: 806
  year: 2022
  ident: 2023060113241511500_keac632-B5
  article-title: Antiviral proinflammatory phenotype of monocytes in anti-MDA5 antibody-associated interstitial lung disease
  publication-title: Rheumatology (Oxford)
  doi: 10.1093/rheumatology/keab371
– volume: 52
  start-page: 1571
  year: 2005
  ident: 2023060113241511500_keac632-B3
  article-title: Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis
  publication-title: Arthritis Rheum
  doi: 10.1002/art.21023
– volume: 12
  start-page: 217
  year: 2022
  ident: 2023060113241511500_keac632-B7
  article-title: Leukemia inhibitory factor: an important cytokine in pathologies and cancer
  publication-title: Biomolecules
  doi: 10.3390/biom12020217
SSID ssj0005138
Score 2.4129114
Snippet Abstract Objectives Anti-melanoma differentiation-associated gene 5 (MDA5) antibody-positive rapidly progressive interstitial lung disease (RP-ILD) is a...
Anti-melanoma differentiation-associated gene 5 (MDA5) antibody-positive rapidly progressive interstitial lung disease (RP-ILD) is a life-threatening disease,...
SourceID proquest
pubmed
crossref
oup
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 2267
SubjectTerms Aged
Amino Acyl-tRNA Synthetases
Autoantibodies
Dermatomyositis
Female
Humans
Interferon-Induced Helicase, IFIH1 - genetics
Leukemia Inhibitory Factor - genetics
Lung Diseases, Interstitial - etiology
Prognosis
Retrospective Studies
Title Relevance of leukaemia inhibitory factor to anti-melanoma differentiation-associated gene 5 antibody-positive interstitial lung disease
URI https://www.ncbi.nlm.nih.gov/pubmed/36326445
https://www.proquest.com/docview/2731718258
Volume 62
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3bjtMwELXKIiFeEPctNxmJB6TKbBLHcfqIYJdddrtIq1YqvESO46hR2gS1CaL8AH_A9zKJnTRVF1F4sdqRL2nO6Xhsj2cQeiWYkK7klFA_cogbO4oMlccIjSxbRa6MeR2JaXTpnU7cj1M27fV-dbyWyiJ8I39ce6_kf1AFGeBa3ZL9B2TbTkEAnwFfKAFhKPfC-Kq6HF77_IPJN1dlKtQiEYMkmyVhUp-e63Q6lYEJbzAhCzUXWb4QbV6UQiNDhEEJzE8YTQ1YXT_MozXRbl3fVB1ZYlm5FlSb7HNQElunO02Q75kqwQjWkZ2qUKbfG-95ky6ks_VwJmfJoqwTHQ0-l2nSylOlc2kny3zdkZ-D_lnVSYgHV8mqnU--qCxZ152M8jTvbmM4dONuZTSv6znEomazU10jM-raczq03NK9jk7ssTMp6IBZy87vh68pzDheM1o3Cvflp-BkcnERjI-n4xvopgNkrTJjvD8737gO2XWG9PbxmiuZQ3rUHeXIjLFl8mxdo9xZzdRWzfguumOWI_it5tY91FPZfXRrZBwuHqCfLcVwHuOWYnhDMawphoscb1EM_5liuKIYZniHYrhLMVxRDBuKPUSTk-Pxu1NicncQSV1eEBbHLg9DHkvH5RHY1Tz0fE9Jn0seUhlasRUxWPuGQ5t7tq8iFkdepKSQQwE2q6SP0EGWZ-oQ4YgBsK7LoZ7lxswZSssXoe3LWEmbCd5HtHm9gTSB7av8KvNAO1jQoAtKYEDpI9K2-qoDu_yl_mtAbs-qLxt4A1DW1QmcyFRergJYK9hgDDrM76PHGve2RwotYXHCnuzR-im6vfkPPUMHxbJUz8E4LsIXNVOh_DC1fwPycco2
linkProvider Flying Publisher
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Relevance+of+leukaemia+inhibitory+factor+to+anti-melanoma+differentiation-associated+gene+5+antibody-positive+interstitial+lung+disease&rft.jtitle=Rheumatology+%28Oxford%2C+England%29&rft.au=Ichimura%2C+Yuki&rft.au=Ikei%2C+Hiroyuki&rft.au=Konishi%2C+Risa&rft.au=Zeniya%2C+Moko&rft.date=2023-06-01&rft.issn=1462-0332&rft.eissn=1462-0332&rft.volume=62&rft.issue=6&rft.spage=2267&rft_id=info:doi/10.1093%2Frheumatology%2Fkeac632&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1462-0324&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1462-0324&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1462-0324&client=summon